Skip to main content

Ultrasound method restores dopaminergic pathway in brain at Parkinson's early stages

While there are several thousand drugs available to treat a wide range of brain diseases, from depression to schizophrenia, they cannot penetrate the blood-brain barrier (BBB) into the brain. The BBB, which protects the brain from pathogens that may be present in blood, also prevents most drugs from gaining access to the brain functional tissue, the parenchyma, a well-known challenge to the treatment of all brain diseases including neurodegenerative disorders like Parkinson's disease and Alzheimer's.
A team led by Elisa Konofagou, Robert and Margaret Hariri Professor of Biomedical Engineering and Professor of Radiology (Physics) at Columbia Engineering, has been developing a novel technique that could open up new ways to facilitate targeted drug delivery into the brain and enable drugs to treat brain diseases more focally. The researchers used transcranial, focused ultrasound and intravenously injected microbubbles into the BBB to make a localized and transient opening that allows drugs to cross through the BBB reversibly and non-invasively. Focusing on Parkinson's disease, in collaboration with Serge Przedborski's group in the department of neurology at Columbia University Irving Medical Center, they discovered that protein delivery and gene delivery across the BBB can partly restore the dopaminergic pathways, the neurons in the brain that are affected in early Parkinson's disease.
"We found both behavioral and anatomical neuronal improvements in the brain," says Konofagou, who led the study, published online on April 4 by the Journal of Controlled Release, and in print June 10. "This is the first time that anyone has been able to restore a dopaminergic pathway with available drugs at the early stages of Parkinson's disease. We were able to curb the rapid progression of neurodegeneration while improving the neuronal function. We expect our study will open new therapeutic avenues for the early treatment of central nervous system diseases."
The team targeted the brain regions involved in early stage Parkinson's and Alzheimer's disease, such as the putamen and hippocampus. The tool they developed for the study is a device that uses a neuronavigation system to direct the treatment in real-time. The U.S. FDA has just assigned the team an Investigational Device Exemption (IDE) to use the device in clinical trials to test its safety in Alzheimer's patients.
"Neurosurgeons use such systems all the time to guide them for neurosurgery," says Antonios Pouliopoulos, associate research scientist in Konofagou's lab who worked on the development of the clinical neuronavigation system. "Our group just replaced the surgical instrument with an ultrasound transducer to perform our non-invasive procedure."
Konofagou's Ultrasound Elasticity and Imaging Laboratory is the only academic lab in the U.S. to receive FDA approval for ultrasound-assisted, blood-brain-barrier opening. Other groups doing similar research either use nanoparticles to facilitate drug delivery or require MRI to guide the procedure. Konofagou's approach is MRI-independent and does not require any nanoparticles.
Her device is a single-element transducer that is much smaller, faster, and less expensive than current helmet-shaped, 1024-element transducer systems that use MRI guidance. Because Konofagou's system is portable, doctors will be able to treat patients anywhere in a hospital and, in the future, even at a patient's home. Treatment can be completed in less than 30 minutes, compared to three to four hours for MRI-guided therapy, and monitored in real-time, a unique feature of the new device. The cost is 10 times less than the MRI-guided helmet. The first trial with the device will be with Alzheimer's patients, after which Konofagou plans to work with Parkinson's patients.
Konafagou recently won a four-year $2.5M NIH grant to use a similar device for deep brain stimulation aiming to unveil the mechanism by which ultrasound excites neurons and to monitor the unveiled mechanism in human subjects. In addition, she will be honored with the 2019 Engineering in Medicine and Biology Society's Technical Achievement Award in Berlin this July for her "outstanding and pioneering contributions in the field of ultrasound imaging and therapy, and their application and clinical translation to the diagnosis of cardiovascular diseases, tumor diagnosis and treatment as well as brain drug delivery and stimulation."
"We all have loved ones with neurodegenerative disorders," Konofagou adds. "My grandmother has been suffering from dementia for more than five years, so I know first-hand how essential it would be to have a simple device that can be wheeled into the patient's home and offer a higher quality of life, especially for our rapidly aging population. And there are so many deadly diseases like brain tumors that affect people of all ages, with no cure yet in sight. That's why we want to bring our research so rapidly to the clinic."
Story Source:
Materials provided by Columbia University School of Engineering and Applied Science. Original written by Holly Evarts. 
Note: Content may be edited.

Comments

Post a Comment

Popular posts from this blog

Major surgery associated with small, long term decline in brain functioning

Major surgery is associated with a small long-term decline in cognitive functioning -- equivalent, on average, to less than five months of natural brain ageing, finds a study in  The BMJ  today. But the odds of substantial cognitive decline also increase after surgery -- approximately doubling -- although the likelihood of this is much lower than after admission to hospital for a medical condition, the findings show. Cognitive decline is the gradual loss of brain functioning that occurs with ageing. It often starts decades before the conventional definition of old age and accelerates with ageing and the presence of an increasing number of underlying health conditions. Certain health issues, such as stroke, can lead to a large "step change" in cognitive decline, and there have been concerns that surgery might also do this, with some patients refusing beneficial surgical procedures as a result, say the researchers. Few previous studies have looked at the potential im...
Post a Comment
Read more

Dark matter may be older than the Big Bang

Dark matter, which researchers believe make up about 80% of the universe's mass, is one of the most elusive mysteries in modern physics. What exactly it is and how it came to be is a mystery, but a new Johns Hopkins University study now suggests that dark matter may have existed before the Big Bang. The study, published August 7 in  Physical Review Letters , presents a new idea of how dark matter was born and how to identify it with astronomical observations. "The study revealed a new connection between particle physics and astronomy. If dark matter consists of new particles that were born before the Big Bang, they affect the way galaxies are distributed in the sky in a unique way. This connection may be used to reveal their identity and make conclusions about the times before the Big Bang too," says Tommi Tenkanen, a postdoctoral fellow in Physics and Astronomy at the Johns Hopkins University and the study's author. While not much is known about its origins,...
Post a Comment
Read more

Scientists challenge notion of binary sexuality with naming of new plant species

A collaborative team of scientists from the US and Australia has named a new plant species from the remote Outback. Bucknell University biology postdoctoral fellow Angela McDonnell and professor Chris Martine led the description of the plant that had confounded field biologists for decades because of the unusual fluidity of its flower form. The discovery, published in the open access journal  PhytoKeys , offers a powerful example of the diversity of sexual forms found among plants. The new species of bush tomato discovered in remote Australia provides a compelling example of the fact that sexuality among Earth's living creatures is far more diverse -- and interesting -- than many people likely realize. Bucknell University postdoctoral fellow Angela McDonnell and biology professor Chris Martine led the study following an expedition last year to relocate populations of the new plant, which were first noted by Australian botanists during the 1970s. Herbarium specimens from th...
Post a Comment
Read more